- Home
- MNMD vs VINP Comparison
MNMD vs VINP Comparison
Compare MNMD & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- VINP
- Stock Information
- Founded
- MNMD 2019
- VINP 2009
- Country
- MNMD United States
- VINP Brazil
- Employees
- MNMD N/A
- VINP N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- VINP Investment Managers
- Sector
- MNMD Health Care
- VINP Finance
- Exchange
- MNMD Nasdaq
- VINP Nasdaq
- Market Cap
- MNMD 509.2M
- VINP 593.2M
- IPO Year
- MNMD N/A
- VINP 2021
- Fundamental
- Price
- MNMD $9.61
- VINP $10.16
- Analyst Decision
- MNMD Strong Buy
- VINP Strong Buy
- Analyst Count
- MNMD 7
- VINP 2
- Target Price
- MNMD $24.71
- VINP $13.50
- AVG Volume (30 Days)
- MNMD 1.3M
- VINP 47.6K
- Earning Date
- MNMD 07-31-2025
- VINP 08-12-2025
- Dividend Yield
- MNMD N/A
- VINP 6.45%
- EPS Growth
- MNMD N/A
- VINP N/A
- EPS
- MNMD N/A
- VINP 0.50
- Revenue
- MNMD N/A
- VINP $153,475,995.00
- Revenue This Year
- MNMD N/A
- VINP $67.28
- Revenue Next Year
- MNMD N/A
- VINP $14.33
- P/E Ratio
- MNMD N/A
- VINP $20.06
- Revenue Growth
- MNMD N/A
- VINP 76.11
- 52 Week Low
- MNMD $4.70
- VINP $8.66
- 52 Week High
- MNMD $10.49
- VINP $11.46
- Technical
- Relative Strength Index (RSI)
- MNMD 56.17
- VINP 61.10
- Support Level
- MNMD $7.96
- VINP $9.29
- Resistance Level
- MNMD $10.49
- VINP $10.40
- Average True Range (ATR)
- MNMD 0.55
- VINP 0.34
- MACD
- MNMD -0.06
- VINP 0.07
- Stochastic Oscillator
- MNMD 65.22
- VINP 78.38
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.